Observe Medical ASA: Notice of extraordinary general meeting on 3 July 2025 in connection with the private placement and a contemplated subsequent offering

12 Jun 2025 13:14 CEST

Oslo, 12 June 2025

Reference is made to the announcement made by Observe Medical ASA (the "Company"
or "Observe Medical", and, together with its subsidiaries, the "Group", OSE
ticker "OBSRV") on 11 June 2025, regarding the successfully placed private
placement of new shares in the Company to raise gross proceeds totalling NOK
36,445,000 (the "Private Placement").

An extraordinary general meeting of the Company will be held on 3 July 2025 at
14:00 (CEST) (the "EGM"). The notice of the EGM, including agenda, proposed
resolutions, registration form, a form of proxy and other relevant documents, is
enclosed hereto.

The agenda includes, inter alia, (i) a proposal for a share capital increase to
issue shares by cash contribution in connection with the Private Placement, (ii)
a proposal for a share capital increase to issue shares to Navamedic ASA in
connection with a loan conversion, (iii) a proposal for a board authorisation to
increase the share capital in connection with the contemplated subsequent
offering, (iv) a proposal for a board authorisation to increase the share
capital in connection with set-off/contribution of loans and accounts payable
etc., and (v) a proposal for a board authorisation to increase the share capital
in order to finance further growth etc.

In connection with item (v) mentioned above, reference is made to the notice of
the annual general meeting of the Company (the "AGM Notice"), which was
published through a stock exchange announcement and distributed to the Company's
shareholders on 6 June 2025. In item 15 of the AGM Notice, it was proposed that
the board of directors of the Company is granted an authorisation to increase
the share capital in order to finance further growth etc., limited to 20% of the
issued share capital following the contemplated share capital reduction further
described in item 14 of the AGM Notice. To ensure a proportional and desired
ratio between the size of the board's authorisation to increase the share
capital and the Company's share capital after the share capital reduction and
the Private Placement, the board of directors has resolved to withdraw the
proposal presented in item 15 of the AGM Notice from the agenda of the upcoming
annual general meeting and instead include it in the agenda for the EGM,
allowing the EGM to consider the proposal for a new board authorisation based on
the share capital following the Private Placement.

Reference is made to the notice of the EGM for further information about the
above-mentioned proposals, as well as the other items on the agenda.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

648963_Observe_Medical_ASA_Notice_of_EGM_3_July_2025.pdf
648963_App_3_to_the_EGM_notice_Independent_expert_report.pdf